172 related articles for article (PubMed ID: 24461081)
1. Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use.
Romero V; Peyton C; Gray I; Hemal A; Terlecki R
BMC Urol; 2014 Jan; 14():10. PubMed ID: 24461081
[TBL] [Abstract][Full Text] [Related]
2. Effects of thiazolidinedione in patients with active bladder cancer.
Li R; Metcalfe MJ; Ferguson JE; Mokkapati S; Nogueras González GM; Dinney CP; Navai N; McConkey DJ; Sahai SK; Kamat AM
BJU Int; 2018 Feb; 121(2):244-251. PubMed ID: 28872778
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
[TBL] [Abstract][Full Text] [Related]
4. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
Lewis JD; Ferrara A; Peng T; Hedderson M; Bilker WB; Quesenberry CP; Vaughn DJ; Nessel L; Selby J; Strom BL
Diabetes Care; 2011 Apr; 34(4):916-22. PubMed ID: 21447663
[TBL] [Abstract][Full Text] [Related]
5. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
Fujimoto K; Hamamoto Y; Honjo S; Kawasaki Y; Mori K; Tatsuoka H; Matsuoka A; Wada Y; Ikeda H; Fujikawa J; Koshiyama H
Diabetes Res Clin Pract; 2013 Feb; 99(2):e21-3. PubMed ID: 23228390
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
Tseng CH
J Formos Med Assoc; 2012 Mar; 111(3):123-31. PubMed ID: 22423665
[TBL] [Abstract][Full Text] [Related]
7. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone use and the risk of bladder cancer.
Kuo HW; Tiao MM; Ho SC; Yang CY
Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
[TBL] [Abstract][Full Text] [Related]
11. [Pioglitazone and the risk of bladder cancer].
Kado T; Usui I; Tobe K
Nihon Rinsho; 2016 Apr; 74 Suppl 2():442-6. PubMed ID: 27266132
[No Abstract] [Full Text] [Related]
12. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
Lee MY; Hsiao PJ; Yang YH; Lin KD; Shin SJ
PLoS One; 2014; 9(1):e85479. PubMed ID: 24427312
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone causing urinary bladder cancer? While waiting for the result of the debate, suggestions for physicians.
Cagiltay E; Tuncel T; Yönem A; Ozdemir G
Eur J Intern Med; 2013 Mar; 24(2):e21-2. PubMed ID: 23267737
[No Abstract] [Full Text] [Related]
18. Bladder cancer with pioglitazone: A case-control study.
Malhotra B; Hiteshi P; Khalkho P; Malik R; Bhadada SK; Bhansali A; Shafiq N; Malhotra S; Kumar N; Rajput R; Rastogi A
Diabetes Metab Syndr; 2022 Nov; 16(11):102637. PubMed ID: 36270237
[TBL] [Abstract][Full Text] [Related]
19. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
Azoulay L; Yin H; Filion KB; Assayag J; Majdan A; Pollak MN; Suissa S
BMJ; 2012 May; 344():e3645. PubMed ID: 22653981
[TBL] [Abstract][Full Text] [Related]
20. Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
Garry EM; Buse JB; Gokhale M; Lund JL; Nielsen ME; Pate V; Stürmer T
Diabetes Obes Metab; 2019 Sep; 21(9):2096-2106. PubMed ID: 31087620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
